We are live on ! Find out more
GRCE

Grace Therapeutics
GRCE

24 hedge funds and large institutions have $1.33M invested in Grace Therapeutics in 2021 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

0.07% less ownership

Funds ownership: 0.09% → 0.02% (-0.07%)

8% less capital invested

Capital invested by funds: $1.44M → $1.33M (-$117K)

14% less funds holding

Funds holding: 28 → 24 (-4)

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

Holders
24
Holders Change
-4
Holders Change %
-14.29%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
3
Reduced
1
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$246K
2
VF
Virtu Financial
New York
+$163K
3
Jane Street
Jane Street
New York
+$72.7K
4
EDRH
Edmond de Rothschild Holding
Switzerland
+$72.2K
5
TSS
Two Sigma Securities
New York
+$34.9K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$625K
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$170K
3
Citadel Advisors
Citadel Advisors
Florida
-$89K
4
OC
Oppenheimer & Co
New York
-$73K
5
HF
HRT Financial
New York
-$14K
Name Holding Trade Value Shares
Change 		Change in
Stake
VF
1
Virtu Financial
New York
$548K +$163K +4,701 +33%
Morgan Stanley
2
Morgan Stanley
New York
$227K +$246K +7,091 +885%
Bank of Montreal
3
Bank of Montreal
Ontario, Canada
$145K +$6.48K +187 +4%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$104K – – –
EDRH
5
Edmond de Rothschild Holding
Switzerland
$60K +$72.2K +2,083 New
Jane Street
6
Jane Street
New York
$60K +$72.7K +2,096 New
Two Sigma Advisers
7
Two Sigma Advisers
New York
$31K -$170K -4,906 -82%
TSS
8
Two Sigma Securities
New York
$29K +$34.9K +1,007 New
MMPW
9
Mitchell McLeod Pugh & Williams
Alabama
$27K – – –
SIAP
10
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$24K – – –
PAG
11
Private Advisor Group
New Jersey
$18K – – –
CCM
12
Campbell Capital Management
Florida
$18K +$21.7K +625 New
Squarepoint
13
Squarepoint
New York
$12K +$13.9K +400 New
LPL Financial
14
LPL Financial
California
$11K – – –
SFA
15
Sequoia Financial Advisors
Ohio
$6K – – –
Bank of America
16
Bank of America
North Carolina
$2K – – –
FDCDDQ
17
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.18K – – –
PCIA
18
Prime Capital Investment Advisors
Kansas
$1K – – –
Royal Bank of Canada
19
Royal Bank of Canada
Ontario, Canada
$1K – – –
RE
20
RBC Europe
United Kingdom
$18 – – –
Renaissance Technologies
21
Renaissance Technologies
New York
– -$625K -40,083 Closed
Citadel Advisors
22
Citadel Advisors
Florida
– -$89K -5,699 Closed
OC
23
Oppenheimer & Co
New York
– -$73K -4,687 Closed
HF
24
HRT Financial
New York
– -$14K -936 Closed
Millennium Management
25
Millennium Management
New York
– -$12K -783 Closed
1
2

GRCE Hedge Fund Activity: Q1 2021 in Review

24 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q1 2021, worth a combined $1.33M — down 8.1% from $1.44M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of GRCE and 7 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 3 added.

The largest buyer was Morgan Stanley, adding an estimated $246K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $625K sold.

  • 24 institutional investors held Grace Therapeutics (GRCE) as of Q1 2021, down from 28 in Q4 2020.
  • Funds reported $1.33M of Grace Therapeutics stock for Q1 2021, down 8.1% quarter-over-quarter.
  • 7 funds opened new Grace Therapeutics positions in Q1 2021 and 11 closed out, a net change of -4 holders.
  • The largest Grace Therapeutics buyer in Q1 2021 was Morgan Stanley, an estimated $246K added.
  • The largest Grace Therapeutics seller in Q1 2021 was Renaissance Technologies, an estimated $625K sold.

Based on aggregated 13F filings for Q1 2021.